How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

54 results for

vitamin d

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Increased risk of cancer death in patients with chronic heart failure with a special reference to inflammation-A report from the CHART-2 Study. (PubMed)

30.9%). As compared with patients without HF (Stage A/B, N = 4622), those with HF (Stage C/D, N = 4221) were characterized by higher prevalence of diabetes, previous myocardial infarction, atrial fibrillation, and stroke. During the median 6.5-year follow-up (52,675 person-years), 282 cancer deaths occurred. HF patients had significantly higher cancer mortality than those without HF in both the overall (3.7 vs, 2.8%, hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.12-1.79, P = 0.004

2019 International journal of cardiology

2. Pembrolizumab (Keytruda) - non-small cell lung cancer (NSCLC) in adults.

25 mg/mL concentrate for solution for infusion. Summary of product characteristics. Electronic Medicines Compendium. Last updated 05 April 2019. 2. Merck Sharp & Dohme. Pembrolizumab 50 mg powder for concentrate for solution for infusion. Summary of product characteristics. Electronic Medicines Consortium. Last updated 05 April 2019. 3. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus Chemotherapy for Squamous Non (...) -Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040-51. Epub 2018/10/04. 4. European Medicines Agency (EMA). European Public Assessment Report. Pembrolizumab (Keytruda). EMEA/H/C/003820/II/0060. 31 January 2019. 5. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüs M, Mazières J, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer Study Protocol. New England Journal of Medicine. 2018;379(21):2040-51. 6. Schiller JH, Harrington D, Belani CP, Langer C

2019 Scottish Medicines Consortium

3. Evidence Brief - Barriers and Facilitators to Use of Medications for Opioid Use Disorder

report are welcome and can be sent to Nicole Floyd, Deputy Director, ESP Coordinating Center at Recommended citation: Mackey K, Veazie S, Anderson J, Bourne D, and Peterson K. Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; 2009. Posted final reports (...) across studies. Background The ESP Coordinating Center (ESP CC) is responding to a request from VA's Health Services Research and Development Service (HSR&D) for an evidence brief on barriers to and facilitators of use of buprenorphine and extended-release naltrexone for treatment of opioid use disorder (OUD). Findings from this evidence brief will be used to inform prioritization of questions for a September 2019 State- of-the-Art (SOTA) conference. Methods To identify studies, we searched MEDLINE®

2019 Veterans Affairs Evidence-based Synthesis Program Reports

4. Bioidentical HRT

estrogen does not appear to increase the risk of VTE. Observational and case control data suggest that the use of certain progestogens e.g. dydrogesterone and micronised progesterone (D/MP) may reduce the increased risk of VTE conferred by oral estrogen, compared to that noted with other synthetic progestogens . Cardiovascular risks D/MP have a neutral effect on lipid and glucose metabolism and on vascular tone. The beneficial effects of estrogen are therefore not attenuated as they are with some (...) synthetic progestogens such as medroxyprogesterone acetate which can blunt the increase in HDL cholesterol, increase insulin resistance and reduce arterial compliance. Smaller studies such as KEEPS and ELITE using MP have demonstrated superior outcomes to WHI. Breast cancer D/MP have pro-apoptotic or neutral effects on breast epithelial cell proliferation – this is in contradistinction to the effects of androgenic progestogens such as medroxyprogesterone acetate which have a proliferative effect. Data

2019 Publication 4890889

5. Health Benefits and Potential Risks of Urban Agriculture: A Focused Practice Question

DESCRIPTION OF INCLUDED PAPERS 6 8 SYNTHESIS OF FINDINGS 8 9 IMPLICATIONS FOR PRACTICE 10 10 RECOMMENDATIONS 13 REFERENCES 14 APPENDICES 15 APPENDIX A: SEARCH STRATEGY 16 APPENDIX B: LITERATURE SEARCH FLOWCHART 20 APPENDIX C: DATA EXTRACTION TABLES 21 APPENDIX D- GUIDE FOR SOIL TESTING IN URBAN GARDENS 34 1 Key Messages The health benefits associated with urban agriculture include: 1. increased access to healthy food; 2. increased vegetable and fruit consumption; 3. increased physical activity; 4 (...) healthy food access, fruit and vegetable consumption, physical activity, mental health, quality of life, and general well-being). 4. Increase gardeners’ awareness of the potential risk of soil pollution; and direct them to Toronto Public Health’s Guide for Soil Testing in Urban Gardens (Appendix D) to help gardeners determine if soil conditions are appropriate for agriculture. 5. Determine programming opportunities among groups that may be interested in implementing urban agriculture programs (e.g

2019 Peel Health Library

6. Twin and triplet pregnancy

and amnionicity. [2011, amended 2019] [2011, amended 2019] 1.1.11 If transabdominal ultrasound scan views are poor because of a retroverted uterus or a high BMI, use a transvaginal ultrasound scan to determine chorionicity and amnionicity. [2011, amended 2019] [2011, amended 2019] 1.1.12 Do not use 3-dimensional (3-D) ultrasound scans to determine chorionicity and amnionicity. [2011, amended 2019] [2011, amended 2019] 1.1.13 Networks should agree care pathways for managing all twin and triplet pregnancies

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic

to detect drug abuse in pregnancy: a brief review. Drug Alcohol Depend . 1999 ; 53 : 257–271 , x 15 Beatty, J.R., Chase, S.K., and Ondersma, S.J. A randomized study of the effect of anonymity, quasi-anonymity, and certificates of confidentiality on postpartum women’s disclosure of sensitive information. Drug Alcohol Depend . 2014 ; 134 : 280–284 , x 16 Markovic, N., Ness, R.B., Cefilli, D., Grisso, J.A., Stahmer, S., and Shaw, L.M. Substance use measures among women in early pregnancy. Am J Obstet (...) ,” “weekly,” “daily,” or “almost daily”: In the past year, how often have you: (1) had ≥4 drinks a day? (2) used tobacco products? (3) used prescription drugs for nonmedical reasons? (4) used illegal drugs? Although the component questions of the NIDA Quick Screen have been validated separately for the identification of the use of individual substances, the package of 4 questions has not yet been examined as a whole for pregnancy screening. x 33 Smith, P.C., Schmidt, S.M., Allensworth-Davies, D

2019 Society for Maternal-Fetal Medicine

8. Evidence for smoking quitlines

Evidence was then summarised according to the NHMRC matrix grading system for recommendation (Table 2). Components evaluated included the evidence base, consistency, clinical impact, generalisability and applicability. 16 EVIDENCE FOR SMOKING QUITLINES | SAX INSTITUTE Table 2: NHMRC matrix of evidence quality Component A B C D Excellent Good Satisfactory Poor Evidence base Several level I or II studies with low risk of bias One or two level II studies with low risk of bias or a systematic review

2019 Sax Institute Evidence Check

10. Society of Interventional Radiology Training Guidelines for Endovascular Stroke Treatment

Dr., Suite 400 N., Fairfax, VA 22033 , x Mazen K. AbuAwad Affiliations Department of Radiology, NCH HealthCare System, Naples, Florida , MD b , x Sun Ho Ahn Affiliations Department of Diagnostic Imaging and Division of Interventional Radiology, Warren Alpert Medical School of Brown University, Providence, Rhode Island , MD c , x Mark O. Baerlocher Affiliations Department of Radiology, Royal Victoria Hospital, Barrie, Ontario, Canada , MD d , x Paul S. Brady Affiliations Department of Radiology (...) Section of Interventional Radiology, Einstein Health Care Network, Philadelphia, Pennsylvania , MD e , x John W. Cole Affiliations Department of Neurology, Maryland Stroke Center, Baltimore VA Medical Center and University of Maryland School of Medicine, Baltimore, Maryland , MD, MS f , x Sabeen Dhand Affiliations Department of Interventional Radiology, Lambert Radiology Medical Group, PIH Health, Whittier, California , MD g , x Benjamin D. Fox Affiliations Department of Neurosurgery and Endovascular

Full Text available with Trip Pro

2019 Society of Interventional Radiology

11. Guidelines on Chronic Coronary Syndromes

at chronic coronary syndrome outpatient clinics 39 Abbreviations and acronyms ABI Ankle−brachial index ACE Angiotensin-converting enzyme ACS Acute coronary syndrome(s) ACTION A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system AF Atrial fibrillation ARB Angiotensin receptor blocker AUGUSTUS An Open-label, 2 × 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo (...) IMT Intima−media thickness IONA Impact Of Nicorandil in Angina iwFR Instantaneous wave-free ratio (instant flow reserve) LAD Left anterior descending LBBB Left bundle branch block LDL-C Low-density lipoprotein cholesterol LM Left main (coronary artery) LV Left ventricular LVEF Left ventricular ejection fraction MI Myocardial infarction MRA Mineralocorticoid receptor antagonist NOAC Non-vitamin K antagonist oral anticoagulant NT-proBNP N-terminal pro-B-type natriuretic peptide OAC Oral

Full Text available with Trip Pro

2019 European Society of Cardiology

12. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD

; T2DM = type 2 diabetes mellitus; VKA = vitamin K antagonist. Table 4 New recommendations in the 2019 Guidelines ABI = ankle–brachial index; ABPM = ambulatory blood pressure monitoring; ACEI = angiotensin-converting enzyme inhibitor; b.i.d. = twice daily (bis in die); b.p.m. = beats per minute; CABG = coronary artery bypass graft; CAC = coronary artery calcium; CAD = coronary artery disease; CKD = chronic kidney disease; CRT = cardiac resynchronization therapy; CRT-D = cardiac resynchronization (...) Carbohydrate 17 Fats 17 Proteins 17 Vegetables, legumes, fruits, and wholegrain cereals 17 Alcohol consumption 17 Coffee and tea 17 Vitamins and macronutrients 17 6.1.2 Physical activity 18 6.1.3 Smoking 18 6.2 Glucose 18 6.2.1 Glycaemic targets 18 Additional glucose targets 18 6.2.2 Glucose-lowering agents 19 6.2.3 Special considerations 19 Hypoglycaemia 19 Glucose monitoring 19 6.3 Blood pressure 20 6.3.1 Treatment targets 20 6.3.2

Full Text available with Trip Pro

2019 European Society of Cardiology

13. Management of Rhinosinusitis in Adolescents and Adults

of Rhinosinusitis in Adolescents and Adults 19 ABRS is unproven. 19, level III In local context, decongestants is prescribed in ARS. • Topical decongestants should not be prescribed for more than two weeks due to rebound phenomenon. Oral decongestants should be cautiously prescribed in those with medical conditions such as diabetes mellitus, cardiovascular diseases, glaucoma and benign prostate hyperplasia. c. Mucolytics There is no evidence to support the use of mucolytics in RS. 1, level III d. Antiviral (...) ):327–34 4. Reh DD, Lin SY, Clipp SL, et al. Secondhand tobacco smoke exposure and chronic rhinosinusitis: A population-based case-control study. Am J Rhinol Allergy. 2009;23(6):562–7 5. Jarvis D, Newson R, Lotvall J, et al. Asthma in adults and its association with chronic rhinosinusitis: The GA2LEN survey in Europe. Allergy Eur J Allergy Clin Immunol. 2012;67(1):91–8 6. Tan BK, Chandra RK, Pollak J, et al. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J

2019 Ministry of Health, Malaysia

15. Management of Stroke Rehabilitation

. About this Clinical Practice Guideline 7 A. Methods 7 a. Grading Recommendations 8 b. Reconciling 2010 Clinical Practice Guideline Recommendations 10 c. Peer Review Process 11 B. Summary of Patient Focus Group Methods and Findings 11 C. Conflicts of Interest 12 D. Scope of this Clinical Practice Guideline 13 E. Highlighted Features of this Clinical Practice Guideline 13 F. Patient-centered Care 13 G. Shared Decision Making 14 H. Co-occurring Conditions 14 I. Implementation 14 IV. Guideline Work (...) Group 15 V. Algorithm 17 A. Module A: Rehabilitation Disposition of the Inpatient with Stroke 18 B. Module B: Outpatient/Community-Based Rehabilitation 19 VI. Recommendations 23 A. Approach and Timing 27 B. Motor Therapy 30 a. Upper and Lower Limbs Rehabilitation 30 b. Technology-Assisted Physical Rehabilitation 37 c. Pharmacological Treatment in Motor Therapy 45 C. Dysphagia Therapy 48 D. Cognitive, Speech, and Sensory Therapy 55 a. Cognitive Therapy 55 b. Speech Therapy 56 c. Spatial Neglect

2019 VA/DoD Clinical Practice Guidelines

16. Assessment and Management of Patients at Risk for Suicide

Affairs Populations 8 C. Identifying Suicide Risk in VA and DoD Populations 9 III. About this Clinical Practice Guideline 10 A. Methods 11 a. Grading Recommendations 12 b. Reconciling 2013 Clinical Practice Guideline Recommendations 13 c. Peer Review Process 14 B. Summary of Patient Focus Group Methods and Findings 14 C. Conflicts of Interest 16 D. Scope of this Clinical Practice Guideline 16 E. Highlighted Features of this Clinical Practice Guideline 17 F. Patient-centered Care 17 G. Shared Decision (...) Making 17 H. Co-occurring Conditions 18 I. Implementation 18 IV. Guideline Work Group 19 V. Algorithm 20 Algorithm A: Identification of Risk for Suicide 21 Algorithm B: Evaluation by Provider 22 Algorithm C: Management of Patients at Acute Risk for Suicide 25 VII. Recommendations 27 A. Screening and Evaluation 29 a. Screening 29 b. Evaluation 31 B. Risk Management and Treatment 35 a. Non-pharmacologic Treatments 35 b. Pharmacologic Treatments 41 c. Post-acute Care 44 d. Technology-based Modalities 47

2019 VA/DoD Clinical Practice Guidelines

17. BHIVA and BIA guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis

, NHS Lothian Infection Service, Edinburgh, UK D O’Shea, University of Edinburgh and Regional Infectious Diseases Unit, NHS Lothian Infection Service, Edinburgh, UK JD Cartledge, Mortimer Market Centre, London, UK AR Freedman, Cardiff University School of Medicine, Cardiff, UK × BHIVA Login Login Download BHIVA apps © Copyright British HIV Association (BHIVA) 2019 Registered Charity Number 1170707 ')

2019 British HIV Association

18. Frequently Asked Questions on Position Statement – Testing for Ovarian Cancer in Asymptomatic Women

website. What are the symptoms of ovarian cancer? It is important that all women are aware of the symptoms of ovarian cancer. The most common symptoms of ovarian cancer are: abdominal bloating or increased abdominal size abdominal or pelvic pain appetite loss, feeling full quickly or indigestion urinary changes, such as frequency or urgency changes in bowel habit, such as constipation unexplained weight loss or weight gain u n e x p l a in e d f a t i gu e . These symptoms can be vague and similar

2019 Cancer Australia

19. Effects of trauma-informed approaches in schools: A systematic review

of trauma and school‐based intervention research. 5.2.1 Electronic databases a. Academic Search Complete b. Database of Research on International Education c. Education Source d. ERIC e. MEDLINE f. ProQuest Dissertations and Theses g. PsycINFO h. Social Science Citation Index i. CINAHL 5.2.2 Search terms and keywords We used combinations of terms related to the intervention, population, study design, and setting to search the electronic databases. Database‐specific strategies were explored for each

Full Text available with Trip Pro

2019 Campbell Collaboration

20. Management of symptomatic hypermobility in children and young people

, Fischer, D et al. Sports-specialized intensive Training and the Risk of Injury in Young Athletes. The American Journal of Sports Medicine Feb 2015 Hill JC, Kang S, Benedetto E, et al. Development and initial cohort validation of the Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal care pathways BMJ Open 2016;6:e012331. doi: 10.1136/bmjopen-2016-012331 Kemp, S, Roberts, I et al. A randomised Comparative Trial of general vs targeted physiotherapy (...) in the management of childhood hypermobility. Rheumatology, vol 49, issue 2, Feb 2010 p315-325 Klein D, Goldenring J, Adelman W. HEEADSSS 3.0 The Psychosocial Interview for Adolescents Updated for a New Century Fuelled by Media. Contemporary Paediatrics 2014, 16-28 Maillard SM, Adkins D, Haggart E, Bhagat S. Physiotherapy Management of Children with Hypermobility: A Review of an Out-Patient Self-Management Exercise Programme. [abstract]. Arthritis Rheum 2010;62 Suppl 10 :1342 Malfait, M, Francomano, C et al

2019 British Society for Rheumatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>